查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570852

抗組織胺市場：按藥物類型、給藥途徑、治療疾病、最終用戶、劑型分類 - 全球預測 2025-2030

Antihistamine Drugs Market by Drug Type, Route Of Administration, Diseases Treated, End User, Formulation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗組織胺市場價值2.6534億美元，預計到2024年將達到2.7974億美元，複合年成長率為5.31%，到2030年將達到3.8139億美元。

抗組織胺市場範圍包括透過阻斷組織胺受體來治療過敏反應的藥物。這些藥物對於治療過敏性鼻炎、結膜炎、蕁麻疹和異位性皮膚炎等疾病至關重要。最終用戶主要包括季節性過敏患者、醫療保健提供者以及依賴非處方藥和處方箋的醫療機構。由於環境因素和遺傳傾向導致全世界過敏症盛行率不斷增加，對抗組織胺的需求持續增加。對過敏相關疾病的認知不斷提高以及藥物的獲取便捷正在推動市場需求。影響市場的主要成長要素包括過敏原發生率的上升、非鎮靜藥物製劑新興市場的開拓以及更容易過敏的老年人口的不斷成長。開發針對特定過敏反應的治療方法以及對自然療法不斷成長的需求也具有潛力。公司應專注於第二代和第三代抗組織胺等創新，以最大限度地減少副作用並提高療效，並探索與其他療法的聯合治療。然而，市場面臨一些限制，例如監管障礙和與某些抗組織胺相關的副作用，例如嗜睡，尤其是對於老年人。此外，學名藥供應量的增加可能會導致價格競爭並影響利潤率。此外，區分高度相似的抗組織胺藥物仍然是一個挑戰。需要創新，重點關注新的給藥方法，例如兒科滴鼻劑和咀嚼片，並將其用途擴大到其他治療領域，例如慢性搔癢症。市場競爭較少，重點是探索更安全、更有效的配方和替代療法，推動永續的業務成長，並開闢新的途徑來解決快速增加的過敏率和多樣化的應用。

主要市場統計
基準年[2023] 26534萬美元
預測年份 [2024] 27974萬美元
預測年份 [2030] 3.8139 億美元
複合年成長率（%） 5.31%

市場動態：揭示快速發展的抗組織胺市場的關鍵市場洞察

供需的動態交互作用正在改變抗組織胺市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本和採購成本的影響，也可以更清楚地了解其影響。

波特的五力：駕馭抗組織胺市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗組織胺市場的外部影響

外部宏觀環境因素在塑造抗組織胺市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗組織胺市場的競爭狀況

抗組織胺市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗組織胺市場供應商的績效評估

FPNV 定位矩陣是評估抗組織胺市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪抗組織胺藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，抗組織胺市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地過敏性疾病和過敏症狀的盛行率不斷增加，抗組織胺的需求不斷增加。
      • 提高患者對過敏的認知和積極管理有助於市場成長
      • 增加非處方抗組織胺的可得性和可用性，提高消費者的承受能力
    • 抑制因素
      • 影響處方抗組織胺銷售的價格敏感度和報銷問題
    • 機會
      • 加強與醫療專業人員和過敏症專家的合作
      • 開發兒童友善抗組織胺藥，擴大兒科過敏市場
    • 任務
      • 抗組織胺作為替代療法越來越受歡迎和偏愛
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 抗組織胺市場：依藥物類型

  • 介紹
  • 第一代H1抗組織胺藥
    • 烷基胺
    • 乙醇胺
    • 乙二胺
    • 吩噻嗪
  • H2抗組織胺藥
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 鼻用抗組織胺藥
    • 左卡巴斯汀
    • 奧洛他定
  • 第二代H1抗組織胺藥
    • 阿克伐斯汀
    • 西替利嗪
  • 外用 H1 抗組織胺藥
    • 氮卓斯汀
    • 奧洛他定

第7章 抗組織胺市場：依給藥途徑

  • 介紹
  • 鼻腔給藥
    • 降低
    • 噴
  • 口服給藥
    • 膠囊
    • 糖漿
    • 錠劑
  • 局部給藥
    • 奶油
    • 凝膠

第8章抗組織胺市場：依治療疾病分類

  • 介紹
  • 過敏性鼻炎
    • 常年性過敏性鼻炎
    • 季節性過敏性鼻炎
  • 慢性蕁麻疹

第9章 抗組織胺市場：依最終用戶分類

  • 介紹
  • 診所
  • 居家醫療
  • 醫院

第10章抗組織胺市場：按劑型

  • 介紹
  • 液體配方
    • 糖漿
  • 固態製劑
    • 膠囊
    • 錠劑

第11章美洲抗組織胺市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太抗組織胺藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗組織胺市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C62918790

The Antihistamine Drugs Market was valued at USD 265.34 million in 2023, expected to reach USD 279.74 million in 2024, and is projected to grow at a CAGR of 5.31%, to USD 381.39 million by 2030.

The scope of the antihistamine drugs market encompasses pharmaceuticals used to treat allergic reactions by blocking histamine receptors. These drugs are essential in managing conditions like allergic rhinitis, conjunctivitis, urticaria, and atopic dermatitis. End-users largely include patients with seasonal allergies, healthcare providers, and institutions relying on over-the-counter and prescription formulations. The necessity of antihistamines continues to rise due to increasing prevalence of allergies worldwide, driven by environmental factors and genetic predispositions. The growing awareness of allergy-related ailments and accessibility to medication boost market demand. Key growth factors influencing the market include the rising incidence of allergens, developments in drug formulation offering non-sedative properties, and an expanding geriatric population who are more susceptible to allergies. The market also sees potential opportunities in developing targeted therapies for specific allergic responses and the growing demand for natural remedies. Companies should focus on innovations such as second- and third-generation antihistamines that minimize adverse effects and enhance efficacy, as well as exploring combinations with other therapeutic agents. However, the market faces limitations such as regulatory hurdles and the adverse effects associated with some antihistamines, like drowsiness, especially in older adults. Additionally, the increasing availability of generic drugs can lead to price competitions, impacting profit margins. Furthermore, a challenge persists in distinguishing antihistamine products amidst vast similarities. Innovations should focus on novel delivery methods, such as nasal sprays and chewable tablets for pediatric use, and expanding usage to other therapeutic areas like chronic pruritis. The market exhibits a moderately competitive nature with an emphasis on research for safer, more effective formulations and alternative therapies, fostering sustained business growth and opening new avenues for tackling burgeoning allergy rates and diversified applications.

KEY MARKET STATISTICS
Base Year [2023] USD 265.34 million
Estimated Year [2024] USD 279.74 million
Forecast Year [2030] USD 381.39 million
CAGR (%) 5.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antihistamine Drugs Market

The Antihistamine Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of allergic diseases and conditions worldwide boosting the demand for antihistamine drugs
    • Increasing awareness and proactive management of allergies among patients contributing to market growth
    • Growing over-the-counter availability and accessibility of antihistamine medications enhancing consumer purchase ease
  • Market Restraints
    • Price sensitivity and reimbursement issues affecting sales of prescription antihistamines
  • Market Opportunities
    • Increasing partnerships with healthcare providers and allergy specialists
    • Developing pediatric-friendly antihistamine drugs to capture the growing children's allergy market
  • Market Challenges
    • Rising popularity and preference for alternative therapies over antihistamine drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antihistamine Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antihistamine Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antihistamine Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antihistamine Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antihistamine Drugs Market

A detailed market share analysis in the Antihistamine Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antihistamine Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antihistamine Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antihistamine Drugs Market

A strategic analysis of the Antihistamine Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antihistamine Drugs Market, highlighting leading vendors and their innovative profiles. These include Alcon Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Meda AB, Merck Group, Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Antihistamine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across First-Generation H1-Antihistamines, H2-Antihistamines, Nasally Administered Antihistamines, Second-Generation H1-Antihistamines, and Topical H1-Antihistamines. The First-Generation H1-Antihistamines is further studied across Alkylamines, Ethanolamines, Ethylenediamines, and Phenothiazines. The H2-Antihistamines is further studied across Cimetidine, Famotidine, Nizatidine, and Ranitidine. The Nasally Administered Antihistamines is further studied across Levocabastine and Olopatadine. The Second-Generation H1-Antihistamines is further studied across Acrivastine and Cetirizine. The Topical H1-Antihistamines is further studied across Azelastine and Olopatadine.
  • Based on Route Of Administration, market is studied across Nasal Administration, Oral Administration, and Topical Administration. The Nasal Administration is further studied across Drops and Sprays. The Oral Administration is further studied across Capsules, Syrups, and Tablets. The Topical Administration is further studied across Creams and Gels.
  • Based on Diseases Treated, market is studied across Allergic Rhinitis and Chronic Urticaria. The Allergic Rhinitis is further studied across Perennial Allergic Rhinitis and Seasonal Allergic Rhinitis.
  • Based on End User, market is studied across Clinics, Home Care, and Hospitals.
  • Based on Formulation, market is studied across Liquid Formulations and Solid Formulations. The Liquid Formulations is further studied across Syrups. The Solid Formulations is further studied across Capsules and Tablets.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of allergic diseases and conditions worldwide boosting the demand for antihistamine drugs
      • 5.1.1.2. Increasing awareness and proactive management of allergies among patients contributing to market growth
      • 5.1.1.3. Growing over-the-counter availability and accessibility of antihistamine medications enhancing consumer purchase ease
    • 5.1.2. Restraints
      • 5.1.2.1. Price sensitivity and reimbursement issues affecting sales of prescription antihistamines
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing partnerships with healthcare providers and allergy specialists
      • 5.1.3.2. Developing pediatric-friendly antihistamine drugs to capture the growing children's allergy market
    • 5.1.4. Challenges
      • 5.1.4.1. Rising popularity and preference for alternative therapies over antihistamine drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antihistamine Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. First-Generation H1-Antihistamines
    • 6.2.1. Alkylamines
    • 6.2.2. Ethanolamines
    • 6.2.3. Ethylenediamines
    • 6.2.4. Phenothiazines
  • 6.3. H2-Antihistamines
    • 6.3.1. Cimetidine
    • 6.3.2. Famotidine
    • 6.3.3. Nizatidine
    • 6.3.4. Ranitidine
  • 6.4. Nasally Administered Antihistamines
    • 6.4.1. Levocabastine
    • 6.4.2. Olopatadine
  • 6.5. Second-Generation H1-Antihistamines
    • 6.5.1. Acrivastine
    • 6.5.2. Cetirizine
  • 6.6. Topical H1-Antihistamines
    • 6.6.1. Azelastine
    • 6.6.2. Olopatadine

7. Antihistamine Drugs Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Nasal Administration
    • 7.2.1. Drops
    • 7.2.2. Sprays
  • 7.3. Oral Administration
    • 7.3.1. Capsules
    • 7.3.2. Syrups
    • 7.3.3. Tablets
  • 7.4. Topical Administration
    • 7.4.1. Creams
    • 7.4.2. Gels

8. Antihistamine Drugs Market, by Diseases Treated

  • 8.1. Introduction
  • 8.2. Allergic Rhinitis
    • 8.2.1. Perennial Allergic Rhinitis
    • 8.2.2. Seasonal Allergic Rhinitis
  • 8.3. Chronic Urticaria

9. Antihistamine Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Home Care
  • 9.4. Hospitals

10. Antihistamine Drugs Market, by Formulation

  • 10.1. Introduction
  • 10.2. Liquid Formulations
    • 10.2.1. Syrups
  • 10.3. Solid Formulations
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Americas Antihistamine Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antihistamine Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antihistamine Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alcon Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca
  • 4. Bayer AG
  • 5. Boehringer Ingelheim
  • 6. Dr. Reddy's Laboratories
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline plc
  • 10. Johnson & Johnson
  • 11. Mallinckrodt Pharmaceuticals
  • 12. Meda AB
  • 13. Merck Group
  • 14. Mylan N.V.
  • 15. Novartis International AG
  • 16. Pfizer Inc.
  • 17. Sanofi
  • 18. Sun Pharmaceutical Industries Ltd
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. ANTIHISTAMINE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIHISTAMINE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIHISTAMINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIHISTAMINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIHISTAMINE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIHISTAMINE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALKYLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ETHANOLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ETHYLENEDIAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY PHENOTHIAZINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY LEVOCABASTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY OLOPATADINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ACRIVASTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CETIRIZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY AZELASTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY OLOPATADINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY PERENNIAL ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SEASONAL ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CHRONIC URTICARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 141. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 184. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 190. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 200. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 201. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 206. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 207. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 209. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 213. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 214. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 215. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 216. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 217. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 222. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 223. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 229. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 230. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 231. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 232. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 233. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 238. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 239. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 245. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 246. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 247. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 248. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 249. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 254. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 255. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 257. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 258. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 261. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 262. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 263. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 264. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 265. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 267. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 270. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 271. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 273. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 278. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 280. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 286. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 287. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 289. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 293. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 294. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 295. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 296. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 297. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 302. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 303. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 305. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 306. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 307. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 309. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 310. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 311. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 312. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID F